Neurocrine Biosciences Inc (NBIX)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	249,700	191,000	176,400	64,000	154,500	58,200	12,200	71,400	89,600	444,800	364,700	402,000	407,300	93,400	204,800	176,500	37,000	21,078	18,042	-39,171
Total stockholders’ equity	US$ in thousands	2,232,000	2,002,100	1,853,000	1,684,500	1,707,800	1,544,600	1,423,400	1,391,100	1,374,000	1,346,000	1,279,200	1,205,600	1,126,200	804,300	831,200	700,300	636,900	574,500	483,700	409,300
ROE		11.19%	9.54%	9.52%	3.80%	9.05%	3.77%	0.86%	5.13%	6.52%	33.05%	28.51%	33.34%	36.17%	11.61%	24.64%	25.20%	5.81%	3.67%	3.73%	-9.57%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $249,700K ÷ $2,232,000K
= 11.19%

Neurocrine Biosciences, Inc.'s return on equity (ROE) has shown varying performance over the past eight quarters. In Q4 2023, the ROE stood at 11.19%, representing an increase from the previous quarter's 9.54%. The upward trend continued from Q2 2023 to Q3 2023, with ROE remaining relatively stable around the 9% mark. However, there was a significant improvement in Q1 2023, with the ROE jumping to 3.80% from the preceding quarter's 9.05%.

Comparing the recent ROE with the corresponding quarters in previous years, we see a notable improvement from the same period in 2022 when the ROE was just 0.86%. This suggests that Neurocrine Biosciences has made progress in utilizing its equity to generate profit for shareholders.

Overall, the trend in ROE for Neurocrine Biosciences, Inc. appears positive, indicating an improvement in the company's ability to generate returns on the equity invested in the business.